Global /Sweden /Healthcare /Medical Devices /PROGEN

Prostatype Genomics AB (publ)

PROGEN

• STO: PROGEN • Delayed

0.8040SEK 2.8%

0.0849 USD

As of 6 June 2026, Prostatype Genomics AB (publ) has a market cap of $4.94M USD, ranking #44545 globally and #728 in Sweden. It ranks #3944 in the Healthcare sector, and #832 in the Medical Devices industry.

Global Rank

44545

Country Rank

728

Sector Rank

3944

Industry Rank

832

Key Stats

Market Cap

$4.94MUSD

46.29M SEK

Enterprise Value

$3.93MUSD

37.22M SEK

Revenue (TTM)

$63.37KUSD

594.0K SEK

EBITDA (TTM)

-$3.88MUSD

-36.75M SEK

Net Income (TTM)

-$4.75MUSD

-44.5M SEK

PS Ratio

77.9

PB Ratio

1.7

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Medical Devices

CEO

Fredrik Rickman open_in_new

Employees

Founded

2007

Website

prostatypegenomics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
2.8%	2.9%	-21%	-55%	34%	157%	-59%	-100%	-100%

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	PROGEN Prostatype Genomics AB Ordinary Shares ISIN: SE0023261532 Shares Out.: Shares Outstanding: 59.189M¹ TV: TradingView: OMXSTO: PROGEN SA: Stock Analysis: STO: PROGEN YF: Yahoo Finance: PROGEN.ST GF: Google Finance: STO: PROGEN BA: Barron's: PROGEN MS: Morningstar: XSTO: PROGEN	0.8040 SEK	TV: TradingView: OMXSTO: PROGEN SA: Stock Analysis: STO: PROGEN YF: Yahoo Finance: PROGEN.ST GF: Google Finance: STO: PROGEN BA: Barron's: PROGEN MS: Morningstar: XSTO: PROGEN
OTC Markets (OTCMKTS / OTC) MIC: OTCM	PGABF Prostatype Genomics AB Ordinary Shares ISIN: SE0023261532 TV: TradingView: OTC: PGABF SA: Stock Analysis: OTC: PGABF YF: Yahoo Finance: PGABF GF: Google Finance: OTCMKTS: PGABF BA: Barron's: PGABF MS: Morningstar: PINX: PGABF	0.3584 USD	TV: TradingView: OTC: PGABF SA: Stock Analysis: OTC: PGABF YF: Yahoo Finance: PGABF GF: Google Finance: OTCMKTS: PGABF BA: Barron's: PGABF MS: Morningstar: PINX: PGABF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.

Similar Companies

Industry: Medical Devices (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Getinge AB (publ) STO: GETI-B	$5.59B 52.4B SEK 113K%	22.2	Sweden
S SciBase Holding AB STO: SCIB	$4.85B 45.5B SEK 98K%	-	Sweden
Elekta AB (publ) STO: EKTA-B	$2.23B 20.86B SEK 45K%	-	Sweden
Vitrolife AB (publ) STO: VITR	$1.59B 14.87B SEK 32K%	-	Sweden
Bonesupport Holding AB (publ) STO: BONEX	$1.53B 14.32B SEK 31K%	78.5	Sweden
Xvivo Perfusion AB (publ) STO: XVIVO	$907.38M 8.5B SEK 18K%	115.1	Sweden

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 4M%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 3M%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 3M%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 3M%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 2M%	38.3	United States
Medtronic plc NYSE: MDT	$101.9B 2M%	22.2	Ireland

chevron_leftBack